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Abstract
Background: Myotonic dystrophy type 1 (DM1) is the most common muscle dystrophy in adults. The disease is
caused by a triplet expansion in the 3’end of the myotonic dystrophy protein kinase (DMPK) gene. In order to
develop a human cell model for investigation of possible effects of antisense and RNAi effector molecules we have
used lentiviral mediated myoD-forced myogenesis of DM1 patient fibroblasts.
Findings: Transduced fibroblasts show a multinuclear phenotype and express the differentiation marker myogenin.
Furthermore, fluorescence in situ hybridization (FISH) analysis revealed a statistical significant increase in the
amount of nuclear foci in DM1 patient fibroblasts after myogenesis. Finally, no nuclear foci were found after
treatment with oligonucleotides targeting the repeat expansions.
Conclusions: The abundance of nuclear foci in DM1 patient fibroblasts increase following myogenesis, as
visualized by FISH analysis. Foci were eradicated after treatment with antisense oligonucleotides. Thus, we propose
that the current cell model is suitable for testing of novel treatment modalities.
Background
Myotonic dystrophy 1 (DM1) is a multisystemic domi-
nant disease and it is the most common muscular dys-
trophy in adults [1]. The symptoms include muscle
wasting (muscular dystrophy), cataract, heart conduction
defects, insulin resistance, and myotonia. The current
treatment is insufficient, ranging from muscle exercise
to breathing assistance. The genetic cause of DM1 is a
(CTG)n repeat in the 3’-untranslated region of the dys-
trophia myotonica protein kinase gene, DMPK [2]. Cur-
rent evidence supports an RNA-gain-of-function
pathogenesis [1]. Indeed, mutant DMPK mRNA localizes
to distinct foci in the nucleus and sequesters multiple
proteins, among these the alternative splicing regulator
muscleblind-like protein 1 (MBNL1). This results in a
depletion of MBNL1 in the nucleus, leading to multiple
events of aberrant splicing. Other factors affected by the
accumulation of foci include CUG-binding protein 1
(CUG-BP1) which is another alternative splicing regula-
tor. Both MBNL1 and CUG-BP1 were recently shown to
regulate the alternative splicing of numerous genes
[3-5]. The importance of the nuclear foci has been
underlined by the discovery that reduction of the num-
ber of foci is associated with normalized splice patterns
in DM1 cells [6,7]. Foci abundancy and brightness has
been reported to increase during myogenesis, but statis-
tical analysis of the number of foci per cell was not per-
formed [8].
To study DM1 pathogenesis in vitro, human DM1
myocytes can be used as model system. However, DM1
patient muscle cells are a scarce resource for research as
a muscle biopsy is required to collect each sample.
Transfer of the myoD gene has previously been shown
to convert fibroblasts into myoblasts [9]. The myoD
protein activates several transcription factors including
myogenin. Inducible overexpression of myoD combined
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with a chloride channel luciferase minigene reporter sys-
tem has been described recently for drug screening in a
cell line [10]. Moreover, immortalized skin fibroblasts
from a Duchenne Muscular Dystrophy patient have
been used in a cell model, where cells were transduced
with an inducible myoD-construct [11]. Here, we have
characterized the reprogramming of DM1 patient fibro-
blasts to muscle cells by demonstrating a muscular phe-
notype and a statistical significant increase in the
number of RNA foci per cell. Furthermore, we have
used the cells for evaluating the treatment effect of pre-
viously described antisense oligonucleotides [7,12].
Methods
Cells and media
Normal human dermal fibroblasts (NHDF) were
obtained from ATCC, USA. DM1 fibroblasts
(GM03132) were from Coriell Institute, USA. Southern
blotting analysis showed that the expanded allele con-
tained approx. 2250 CTG repeats in the DMPK gene.
Standard medium: DMEM from Invitrogen™ with 10%
fetal calf serum (Sigma-Aldrich), glutamine, streptomy-
cin and penicillin. Low serum medium (HS): F12 med-
ium from Invitrogen™ containing 3% horse serum,
glutamine, streptomycin and penicillin.
Lentiviral production and transduction
The lentiviral vector encoding myoD was generated by
replacing the puro gene in pCCL-WPS-PGK-puro-WHV
[13] with myoD cDNA. For lentiviral production, 293T
cells were seeded at 3 × 106 cells/p10 dish in standard
medium, which was refreshed one hour prior to trans-
fection. Cells were transfected by a CaPO4 co-precipita-
tion method with 3.75 μg pMD.2G, 3 μg pRSV-Rev, 13
μg pMDGP-Lg/RRE and 13 μg of transfer vector (either
pCCL-WPS-PGK-MyoD-WHV or pCCL-WPS-PGK-GFP-
WHV). The medium was refreshed 24 hours post-trans-
fection. One day later, supernatant containing the viral
vector was filtered through a 0.45 μm pore filter, and
polybrene added to a final concentration of 8 μg/ml.
The medium was diluted 1:3 with standard medium and
transferred to NHDF and DM1 fibroblasts. Medium was
refreshed 24 hours after transduction.
Quantitative RT-PCR
RNA was isolated and cDNA was synthesized according
to manufacturer’s protocol (Sigma® and BioRad®,
respectively). Before use, the cDNA was thawed and
diluted appropriately; in this range of experiments a
dilution of 1:4 was used. Furthermore, dilutions were
made to set up a standard curve for the reactions. 2 μl
of cDNA 1:4 dilution of each sample was added to 23 μl
solution consisting of 12.5 μl TaqMan® universal PCR
mastermix, 1.25 μl TaqMan mRNA specific primer set
and 9.25 μl H2O. Reaction plates were analyzed by an
ABI Prism® 7000 sequence detection system (Applied
Biosystems). All samples were analyzed as triple deter-
minations. The following TaqMan® assays were used:
myogenin (MYOG, Hs01072232_m1, Applied Biosys-
tems) and myoD (MYOD1, Hs00159528_m1, Applied
Biosystems).
Immunofluorescence (IF)
Human primary fibroblasts were grown in either stan-
dard medium or F12 with 3% horse serum (HS medium)
at 37°C in 5% CO2. The cells were grown to appropriate
confluence and fixed in 4% formaldehyde (Lilly’s solu-
tion) for 10 minutes. After fixation, the cells were
washed 3 times in PBS (137 mM NaCl, 2.7 mM KCl, 10
mM Na2HPO4, 2 mM NaH2PO4 (pH 7.2)). To lower the
non-specific binding, the slide was incubated in 100 μl
1% BSA in PBS (blocking buffer) prior to antibody addi-
tion. Slides were washed in PBS and incubated with 100
μl primary antibody diluted (1:100) in blocking buffer
(BSA-PBS) for 2 hours. 3× wash in PBS followed before
100 μl secondary antibody (1:400) diluted in blocking
buffer, was added. The slide was incubated with second-
ary antibody for 1 hour before it was washed and 100 μl
antifade, with or without DAPI (4’,6-diamidino-2-pheny-
lindole) was added. Primary antibodies were mouse
monoclonal anti-myoD and anti-myogenin (both Santa
Cruz Biotechnology). The secondary antibodies were
Alexa Flour® 488 conjugated goat anti mouse (Invitro-
gen). All secondary antibodies were diluted 1:400 in 1%
BSA PBS solution.
Fluorescence in situ hybridization (FISH)
FISH was performed according to protocol from Singer-
Lab Online [14].
Probes were RP-HPLC purified and labeled with Cy3
(red) purchased from DNA Technology A/S, Denmark.
The Cy3-labeled probe consisted of a (CAG)10-sequence
with a fluorophore at the 5’-end [15]. All reagents used
in the above protocol were nuclease free and dissolved/
diluted in nuclease free/DEPC-treated water or PBS
unless otherwise stated. The numbers of RNA foci were
counted microscopically and compared using Student’s
t-test.
Quantification of foci
The numbers of foci per cell were quantified by two dif-
ferent methods giving essentially similar results. The
first method was based on direct counting, using a
fluorescence microscope. Microscope fields were chosen
randomly, using the DAPI filter, and dots were counted
in all cells where the complete cell was present in the
field. In another method images were acquired. This
was done (in the Cy3 channel), using multidimensional
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acquisition, and images were stacked into a 2d-picture.
The counting was performed by allowing the software
to count the number of foci based on an arbitrary
threshold value for minimum light intensity. Software
used in the image acquisition was MetaMorph, and in
the image processing, including counting, ImageJ was
used.
Combined IF and FISH
Cells were rehydrated and permeabilized according to
the FISH procedure described above. Next, cells were
blocked in 1%BSA solution in a humidified hybridiza-
tion chamber for 1 hour at room temperature. After-
wards, cells were transferred to a new hybridization
chamber and incubated with primary antibodies for
1.5 hours at 37°C. Following this, cells were washed
three times 5 minutes in PBS containing 5 mM MgCl2
at room temperature and thereafter incubated in sec-
ondary antibodies for 45 minutes at 37°C in a humidi-
fied hybridization chamber. Subsequently, cells were
washed five times 5 minutes in PBS containing 5 mM
MgCl2 at room temperature. Cells were fixed in 4%
paraformaldehyde for 20 min at room temperature
and the FISH procedure was performed as described
above.
Transfection with RNA oligonucleotides
Oligonucleotides used in the present study comprised 21
nucleotides. They were chemically modified, as pre-
viously described [7] with a phosphorothioate backbone
(PT) and methylated at 2’O (2’OMe). The antisense oli-
gonucleotide had the sequence (CAG)7, targeting the
pathogenic repeat. The control oligonucleotide had the
following sequence: GUAGCGACUAAACACAUCAAG.
Cells were transferred to glass cover slips in a 12-
well plate with a confluency of 1.5 × 105 cells/well.
The following day, cells were transfected with the oli-
gonucleotide, using polyethyleneimine (PEI) aided by
hyaluronic acid (HA) as transfection reagent (Sigma-
Aldrich). Transfection was performed as previously
described [16].
Oligonucleotides (600 μg/ml), hyaluronic acid (HA)
(Sigma-Aldrich; 3.5 mg/ml) and polyethyleneimine (PEI)
(Sigma-Aldrich; 937.5 μg/ml) were mixed in a 1:2:1 ratio
(by volume). This suspension was diluted in an equal
volume of doubly concentrated PBS. The DNA/HA/PEI/
PBS solution was incubated for 30 minutes at room
temperature. Immediately before adding the complex to
the cells, the medium was refreshed (ordinary DMEM)
and the complex was added to the cells. Cells were
incubated for 4 hours at 37°C with the transfection
complex and the medium was subsequently replaced
with fresh DMEM. Cells were fixed for FISH analysis 24
hours post-transfection.
Results and discussion
Analysis of myoD-transduced primary human fibroblasts
Lentiviral mediated gene transfer was used for expres-
sion of myoD in normal human dermal fibroblasts
(NHDF). Quantitative PCR (qPCR) analysis was used to
determine the expression of myoD and myogenin in
transduced NHDFs. Cell differentiation was enhanced
using low serum medium (HS) containing 3% horse
serum (see materials and methods) [17]. We observed
that myoD was expressed in fibroblasts 6 days after len-
tiviral transduction (Figure 1A). Cells transduced with
GFP and non-transduced cells expressed negligible
quantities of myoD relative to cells transduced with
myoD. The levels of myoD RNA were further increased
in the myoD-transduced cells cultured in HS medium.
Analysis by qPCR likewise showed that the differentia-
tion marker myogenin is expressed in cells transduced
with myoD, and further increased by cultivation in HS
medium (Figure 1B). Immunofluorescence revealed that
both myoD and myogenin could be detected in myoD-
transduced fibroblasts (Figure 1C, D). As expected, both
proteins were located in the nuclei. Neither myoD nor
myogenin were observed in non-transduced or GFP-
transduced cells (data not shown).
myoD-transduction of DM1 fibroblasts leads to a
muscle-like phenotype and increased numbers
of nuclear RNA foci
Having shown myogenesis of normal cells, myoD-trans-
duced DM1 fibroblasts were cultivated in low-serum
medium (HS) for 2-3 weeks. Cellular differentiation was
mediated by lentiviral delivery of the transcription factor
myoD. As seen in Figure 2, myoD-transduced cells dis-
play multinuclear tubular morphology and express myo-
genin (Figure 2B, D), respectively, compared to non-
transduced cells (Figure 2A, B). Fluorescence in situ
hybridization (FISH) using a Cy3-labeled (CAG)10 oligo-
nucleotide probe revealed distinct nuclear foci in DM1
patient fibroblasts (Figure 2G and 2H), whereas no foci
were found in NHDF (Figure 2E, F). Statistical analysis
of the number of foci in myoD-transduced DM1 cells
revealed that transduction with myoD lead to increased
numbers of Cy3-foci per nucleus (Figure 3). The
increased foci abundancy was only seen in myoD-trans-
duced cells with a myogenic phenotype (p < 0.01; Stu-
dent’s t-test) (Figure 3F).
Combined immunostaining and fluorescence in situ
hybridization (IF/FISH) revealed that only cells trans-
duced with myoD had multiple nuclei, tubular mor-
phology and an increased number of nuclear foci
(Figure 4E-H). Furthermore, myogenin was expressed
in all nuclei of cells with multiple nuclei and tubular
morphology (Figure 4F, H). Cell fusion was only found
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between cells in which all nuclei expressed myogenin
(Figure 4F, H). The morphology of myoD-transduced
normal fibroblasts was similar to that observed in
myoD-transduced DM1 patient fibroblasts. Thus, com-
bined immunostaining and fluorescence in situ hybri-
dization confirmed that myogenesis leads to
significantly increased numbers of nuclear RNA foci
per cell.
myoD-transduced DM1 patient fibroblasts can be used for
analysis of treatment effects of antisense oligonucleotides
DM1 patient cells were transfected with antisense oligo-
nucleotides (AONs) targeting the CUG repeat in dmpk
mRNA. Already one day after treatment, FISH revealed
elimination of the nuclear foci, both in non-transduced
and myoD-transduced cells transfected with the AONs
(Figure 5B, D). Transfection with control oligonucleo-
tides with the same length and chemical modifications
did not affect the number of foci (data not shown). It has
previously been shown that the present AONs reduce the
levels of mutant DMPK RNA [7]. However, although eva-
luation of treatment effects 2 days after AON transfec-
tion gave similar results (data not shown), it cannot be
completely ruled out that the observed eradication of foci
could be a consequence of competition between the ther-
apeutic AONs and the labeled FISH probe.
Conclusions
In DM1 muscle cells the transcription factor myoD is
downregulated, and poor muscle differentiation has
been described [18,19]. However, normal myogenin
expression has been shown in developing myoblasts iso-
lated from DM1 patient biopsies [20]. We here show
that lentiviral mediated myoD-transduction leads to
myoD and myogenin expression in both normal and
DM1 fibroblasts, indicating that the impaired differentia-
tion can be overcome at least to some extent. Myogenin
regulates myotube formation and accordingly we
detected myogenin in all nuclei of cells with a myotubu-
lar phenotype (Figure 4H).
Figure 1 Expression of myoD and myogenin in normal human dermal fibroblasts (NHDF). (A and B) The cells were cultured for 6 days
before harvest for quantitative RT-PCR or (C and D) IF: myoD and myogenin expression relative to beta-actin. +HS indicate cells grown in low
serum medium; -HS designates cells grown in standard DMEM medium. Control designates no transduction. (C and D) Immunofluorescence of
myoD and myogenin proteins, respectively. Original magnification × 630.
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Foci of nuclear mutant DMPK is a characteristic mani-
festation of the DM1 disease phenotype. These foci were
visualized by FISH analysis, using a Cy3-labeled CAG-
probe [15,20-25]. The appearance of the foci differed
considerably, both in shape, intensity and area (size). As
previously described, the vast majority were localized to
the nucleus and the intranuclear position was seemingly
random [15]. We observed an increase in the number of
foci in differentiated cells, displaying a mature muscle



















Figure 2 Characterization of DM1 patient fibroblasts (PT) transduced with myoD. (A and B) Light microscopy of PT cells cultured in low
serum medium for 21 days post-transduction. (A) Non-transduced (NT) PT cells display a fibroblast phenotype, (B) PT cells transduced with myoD
display elongated tubular morphology. (D) IF of myogenin in DM1 patient fibroblasts (PT), 12-days post-transduction PT cells express myogenin
and exhibit multinuclear morphology, (C) while non-transduced PT cells do not. (E-H) myoD induced myogenesis increase the number of nuclear
foci in DM1 patient fibroblasts. (G-H) DM1 patient fibroblasts and (E-F) normal fibroblasts were cultured 10 days in low serum medium following
transduction with (E and G) GFP or (F and H) myoD. Cells were analyzed by FISH with a Cy3-labeled (CAG)10 probe (red) targeting the
pathogenic CUG repeat expansion of DMPK mRNA. (E-F) Normal fibroblasts (NHDF) displayed no nuclear foci when transduced with GFP or
myoD. (G-H) DM1 patient fibroblasts exhibited an increased number of nuclear foci in fibroblasts transduced with myoD relative to GFP
transduced fibroblasts. (H) The high number of foci was only observed in myoD transduced fibroblasts with myogenic morphology. (A-B) Original
magnification × 400 and (C-H) × 630.
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reports using retrovirally transduced DM1 fibroblasts [8].
Both NHDF and DM1 patient cells were found to be
responsive to myoD-forced myogenesis (Figure 1 and 2)
as has been reported previously [8-10,25]. However, the
myogenic capability and increase in foci abundancy is
slightly controversial, since earlier reports indicate
decreased differentiation in DM1 cells [18,19]. In con-
trast, a more recent study reported normal myogenesis,
but increased apoptosis in DM1 cells [20]. Indeed, we
observed normal myogenesis in the DM1 cells, and no
obvious signs of increased cell death were seen in the dif-
ferentiated DM1 fibroblasts compared to the differen-
tiated NHDF fibroblasts. Transfection with antisense
oligonucleotides (AONs) can lead to reversal of RNA
toxicity in a DM1 cell model from transgenic mice





Figure 3 Quantification of foci in DM1 patient cells and NHDF. (A and D) Fibroblasts were transduced with GFP or (B, E-F) myoD. Nuclear
foci in 100 cell nuclei were counted for each sample. (A and B) NHDF cell nuclei contained no foci following tranduction with GFP or myoD. (D
and E) PT cells transduced with GFP or myoD showed foci in cell nuclei. (F) Differentiated (myoD) patient fibroblasts displayed markedly changed
morphology and exhibited an increase in the average as well as the maximum number of nuclear foci per cell.
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Figure 4 IF/FISH targeting myogenin (IF) and the (CAG)-repeat (FISH) of transduced DM1 fibroblasts. (A and E) Panels display DAPI
counterstain, (B and F) FITC/GFP channel, (C and G) Cy3 channel, (D and H) merge of DAPI/GFP/Cy3. (A-D) Cells transduced with GFP display no
change in morphology or in the number of Cy3-foci (red) top panel. (E-H) Cells transduced with myoD display a multinuclear morphology, signs
of cell fusion (syncytia), and an increased number of Cy3-foci per nucleus. Primary antibodies target myogenin, secondary antibodies are Alexa
Fluor 488-labeled. The probe is a Cy3-labeled (CAG)10 DNA oligonucleotide. Original magnification × 630.
Figure 5 Treatment of DM1 cells with antisense oligonucleotides. Cells were transfected with 1 μg of oligonucleotides (AON) targeting the
CUG triplet repeat, and RNA foci visualized using FISH with a Cy3-labeled CAG probe (red dots). (C and D) Differentiated DM1 cells cultivated in
HS medium, 2 weeks post-myoD-transduction. (A and B) DM1 fibroblasts. (B and D) Cells transfected with AONs. (A and C) Untransfected.
Original magnification × 630.
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differentiated DM1 cells are applicable as a human cell
model, we reproduced foci reduction in differentiated
human DM1 cells (Figure 5), by transfecting with anti-
sense oligonucleotides previously shown to be capable of
rescuing the phenotype [12]. Thus, myoD-transduced
DM1 cells are capable of myogenic differentiation and
can be used as a cell model for in vitro experiments
studying the cellular pathophysiology and possible effects
of therapeutic compounds on the DM1 phenotype.
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